ACET - Company ID 0001720580
The table below shows Adicet Bio, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$21.49M | -$25.40M | -$22.85M | -$24.09M | $4.11M | -$15.15M |
| Capital expenditure | $37.00K | $1.49M | $239.00K | $1.92M | $2.63M | $658.00K |
| Investing cash flow | $18.88M | -$2.86M | -$239.00K | -$1.92M | -$2.63M | $7.84M |
| Dividends paid | - | - | - |
Adicet Bio, Inc. reported operating cash flow of -$95.25M for fiscal year 2025. That is down 3.1% from -$92.38M in fiscal 2024. Over the 9 fiscal years shown, operating cash flow declined from -$10.98M (FY 2017) to -$95.25M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | -$65.00K | -$104.00K | $110.97M | -$7.00K | -$1.13M | $144.89M |